التفاصيل البيبلوغرافية
العنوان: |
The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis |
المؤلفون: |
Jia-Hui Feng, Jie Cheng, Yao-Jia Lao, Kai Huang, Juan-Li Mou, Fan Hu, Meng-Lu Lin, Jun Lin |
المصدر: |
European Journal of Medical Research, Vol 28, Iss 1, Pp 1-11 (2023) |
بيانات النشر: |
BMC, 2023. |
سنة النشر: |
2023 |
المجموعة: |
LCC:Medicine |
مصطلحات موضوعية: |
Helicobacter pylori, Vonoprazan, Amoxicillin, Dual therapy, Meta-analysis, Medicine |
الوصف: |
Abstract Aim To evaluate the efficacy and safety of vonoprazan–amoxicillin (VA) dual therapy for radically eradicating Helicobacter pylori (H. pylori). Methods The PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang databases were searched up to July 7, 2022, to identify clinical trials comparing the efficacy of VA dual therapy and triple therapy for H. pylori eradication. After evaluating the quality of the included studies, random effects models were conducted, and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to estimate the efficacy and safety of each approach. Results Six publications (including four randomized controlled trials) involving 2019 patients were included in this meta-analysis. Overall, the eradication rate for VA dual therapy was 89.9%, while it was 85.2% for triple therapy based on other acid inhibitors. The eradication rate of H. pylori in the VA dual regimen group was higher than that in the PPI-based (omeprazole or lansoprazole) triple therapy group (RR = 1.15, 95% CI 1.07–1.23, p |
نوع الوثيقة: |
article |
وصف الملف: |
electronic resource |
اللغة: |
English |
تدمد: |
2047-783X |
Relation: |
https://doaj.org/toc/2047-783X |
DOI: |
10.1186/s40001-023-01249-6 |
URL الوصول: |
https://doaj.org/article/9d9d5ea23c6b43598f6437d7218a1aac |
رقم الانضمام: |
edsdoj.9d9d5ea23c6b43598f6437d7218a1aac |
قاعدة البيانات: |
Directory of Open Access Journals |